Clinical Trial: A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer

U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07218146) titled 'A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer' on Oct. 08.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Study Start Date: Nov. 30

Study Type: INTERVENTIONAL

Condition: Small-cell Lung Cancer

Intervention: DRUG: ZL-1310 Dose Level 1

ZL-1310 Dose Level 1 as a single-agent

DRUG: ZL-1310 Dose Level 2

ZL-1310 Dose Level 2 as a single-agent

DRUG: Investigator's Choice of Therapy

Tarlatamab, Topotecan, Lurbinectedin, or Amru...